Niva Bupa Health Insurance Company Limited share price
NSE: NIVABUPA · ISIN INE995S01015
Key numbers
- Market cap
- ₹ 14,277 Cr
- Current price
- ₹ 77.19
- 52-week high / low
- ₹ 91 / 68
- Stock P/E
- 77.2
- Book value
- ₹ 20.7
- Dividend yield
- 0.00%
- ROCE
- 5.4%
- ROE
- 12.1%
- Debt to equity
- 0.08
- Sales growth (3 yrs)
- 36.4%
- Profit growth (3 yrs)
- 118.5%
- 1-year return
- -5.6%
About Niva Bupa Health Insurance Company Limited
Niva Bupa Health Insurance Company Limited provides health insurance products in India. It offers health insurance plans, such as individual, family, NRIs, senior citizens, personal accident, critical illness, disease-specific, hospital cash, and maternity insurance; travel insurance plans, including international and studying abroad insurance; and corporate insurance plans comprising group and start up health, group personal accident, and OPD coverage, as well as group health insurance claim process. The company was formerly known as Max Bupa Health Insurance Company Limited and changed its name to Niva Bupa Health Insurance Company Limited in July 2021. The company was incorporated in 2008 and is based in Gurugram, India. Niva Bupa Health Insurance Company Limited operates as a subsidiary of Bupa Singapore Holdings Pte. Ltd.
Quarterly results
Consolidated figures in ₹ crores
| Mar 2025 | Jun 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|
| Sales | 1,671 | 1,932 | 1,611 | 2,139 | 2,471 |
| Operating profit | 206 | 98 | -88 | 341 | 184 |
| Net profit | 206 | 71 | -88 | 345 | 138 |
| EPS (₹) | 1.13 | 0.39 | -0.47 | 1.87 | 0.75 |
Concall summary (2026-08-03)
AI summary of the earnings call transcript · tone: Positive · source document
Guidance & outlook
- So that's, that's broadly what we are driving, and, we do expect to sustain 8 to 10 percentage points faster than market growth on retail health specifically.
- And on that, we stick to our FY29 guidance, which is what we have been indicating.
Growth & demand
- Retail health at the industry level grew 31.6% and the overall growth as far as health is concerned, you know, on a reported basis was 22.4%.
- As far as Niva Bupa's performance is concerned, on a like-to-like basis, overall we grew at 23.0%; on a reported basis at 31.7%.
Margins & costs
- Just a brief comment that we have seen a challenging pricing environment on the group side.
- And the pricing environment that we discussed last year as well, specifically towards Q3, Q4, we continue to face a challenging pricing environment on the B2B side.
Capex & expansion
- For example, let's say, in some cases, the profit commission, which is mainly on obligatory or voluntary quota share, is booked in one quarter, in some time it is in next quarter.
- Actually, in case of GST, as far as commission is concerned, which is the main line item that we have already passed on to our distributors.
Balance sheet & cash
- We start with; the board has approved formation of debt raising committee and it has also passed enabling resolution to raise up to INR500 crore s in one or more tranches.
- And we're also looking at our growth plans for next 2 years, and basis that we will take decision to raise debt.
Peers in Insurance - Life
Data for information only, not investment advice. Prices end of day.